A novel Munc13-4/S100A10/annexin A2 complex promotes Weibel–Palade body exocytosis in endothelial cells

Tarek Chehab^{a,†}, Nina Criado Santos^{a,†}, Anna Holthenrich^a, Sophia N. Koerdt^a, Jennifer Disse^a, Christian Schuberth^b, Ali Reza Nazmi^a, Maaike Neeft^c, Henriette Koch^d, Kwun Nok M. Man^d, Sonja M. Wojcik^d, Thomas F. J. Martin^e, Peter van der Sluijs^c, Nils Brose^d, and Volker Gerke^{a,*} ^aInstitute of Medical Biochemistry and ^bInstitute of Cell Dynamics and Imaging, Centre for Molecular Biology of Inflammation, Cells-in-Motion Cluster of Excellence, University of Münster, 48149 Münster, Germany; ^cDepartment of Cell Biology, Center of Molecular Medicine, University Medical Center Utrecht, 3584 CX Utrecht, Netherlands; ^dDepartment of Molecular Neurobiology, Max Planck Institute of Experimental Medicine, 37075 Göttingen, Germany; ^eDepartment of Biochemistry, University of Wisconsin–Madison, Madison, WI 53706

ABSTRACT Endothelial cells respond to blood vessel injury by the acute release of the procoagulant von Willebrand factor, which is stored in unique secretory granules called Weibel-Palade bodies (WPBs). Stimulated WPB exocytosis critically depends on their proper recruitment to the plasma membrane, but factors involved in WPB–plasma membrane tethering are not known. Here we identify Munc13-4, a protein mutated in familial hemophagocytic lymphohistiocytosis 3, as a WPB-tethering factor. Munc13-4 promotes histamine-evoked WPB exocytosis and is present on WPBs, and secretagogue stimulation triggers an increased recruitment of Munc13-4 to WPBs and a clustering of Munc13-4 at sites of WPB–plasma membrane contact. We also identify the S100A10 subunit of the annexin A2 (AnxA2)-S100A10 protein complex as a novel Munc13-4 interactor and show that AnxA2-S100A10 participates in recruiting Munc13-4 to WPB fusion sites. These findings indicate that Munc13-4 supports acute WPB exocytosis by tethering WPBs to the plasma membrane via AnxA2-S100A10. Monitoring Editor Keith E. Mostov

University of California, San Francisco

Received: Feb 27, 2017 Revised: Apr 17, 2017 Accepted: Apr 18, 2017

INTRODUCTION

Weibel–Palade bodies (WPBs) are unique secretory organelles of endothelial cells that serve as storage granules for important regulators of vascular homeostasis. Factors that are stored in WPBs for acute release on demand include the coagulant glycoprotein von Willebrand factor (VWF) and the leukocyte receptor P-selectin (for a review, see Sadler, 1998; Wagner and Frenette, 2008). WPBs have an elongated shape that is dictated by the tight packaging of their major cargo, VWF. They form at the *trans*-Golgi network and are then transported along microtubules toward the cell periphery,

Abbreviations used: FHL, familial hemophagocytic lymphohistiocytosis; FP, fluorescent protein; VWF, von-Willebrand factor; WPB, Weibel-Palade body. where they are anchored at the actin cytoskeleton for final maturation (for a review, see Nightingale and Cutler, 2013; Valentijn and Eikenboom, 2013). Exocytosis of the fully matured WPBs is evoked by a varied set of secretagogues, such as histamine and thrombin, which function by eliciting intracellular Ca²⁺ signals, or epinephrine and vasopressin, which elevate intracellular cAMP (for a review, see Datta and Ewenstein, 2001; Nightingale and Cutler, 2013). Typically, acute WPB secretion is initiated after blood vessel injury or local inflammatory activation. It results in a marked change of endothelial surface properties, rapidly transforming the antiadhesive surface of resting endothelial cells, which supports the unrestricted circulation of blood cells, into an adhesive one capable of capturing platelets and leukocytes. Thus controlled WPB exocytosis serves an important role in regulating blood vessel homeostasis.

Several factors involved in WPB maturation and exocytosis have been described. They include the Rab GTPases Rab3, Rab15, and Rab27a and some of their effectors (Knop *et al.*, 2004; Nightingale *et al.*, 2009; Bierings *et al.*, 2012; van Hooren *et al.*, 2012; Zografou *et al.*, 2012). Rab27a is of particular interest, as it is a specific marker for mature WPBs and is also found on other lysosome-related organelles, such as melanosomes, that share certain properties with WPBs

This article was published online ahead of print in MBoC in Press (http://www .molbiolcell.org/cgi/doi/10.1091/mbc.E17-02-0128) on April 27, 2017. ¹These authors contributed equally.

^{*}Address correspondence to: Volker Gerke (gerke@uni-muenster.de).

^{© 2017} Chehab, Santos, et al. This article is distributed by The American Society for Cell Biology under license from the author(s). Two months after publication it is available to the public under an Attribution–Noncommercial–Share Alike 3.0 Unported Creative Commons License (http://creativecommons.org/licenses/by -nc-sa/3.0).

[&]quot;ASCB®," "The American Society for Cell Biology®," and "Molecular Biology of the Cell®" are registered trademarks of The American Society for Cell Biology.




FIGURE 1: Expression and localization of Munc13 proteins in human endothelial cells. (a–d) Western blot (IB) detection of Munc13-1 to -4 in two different HUVEC lysates. Included are positive (+) and negative controls (–), that is, mouse brain lysates (Munc13-1 to -3) or mouse lung lysate (Munc13-4) from wild-type or the respective knockout mouse. Calculated molecular masses are as follows: Munc13-1, 193 kDa; Munc13-2, 180 kDa; Munc13-3, 250 kDa (migrates at ~280 kDa in SDS–PAGE (Varoqueaux *et al.*, 2005); and Munc13-4, 123 kDa. Valosin-containing protein (VCP; 97 kDa) and α-tubulin (55 kDa) served as loading control. In a, the weaker band below Munc13-1 most likely corresponds to Munc13-2, which shows some cross-reactivity with the anti–Munc13-1 antibody (Cooper *et al.*, 2012). The lower band in the HUVEC lysates in c likely stems from an unspecific antibody reaction, as it is not seen in the mouse lysates. (e) RT-PCR of HUVEC cDNA with primers amplifying specific sequences of all human Munc13 proteins (Munc13-1, 243 base pairs; Munc13-2, 159 base pairs; Munc13-4, 201 base pairs). (f) Confocal section of fixed HUVECs labeled with anti–Munc13-4 and anti-VWF antibodies and Alexa Fluor 488– and Alexa Fluor 647–conjugated secondary antibodies. Arrowheads mark examples of colocalizations of Munc13-4 and VWF on WPBs. Scale bar, 10 µm.

(for a review, see Marks *et al.*, 2013). Rab27a is involved in anchoring maturing WPBs at the cortical actin cytoskeleton via a tripartite complex consisting of Rab27a, the Rab27a effector MyRIP, and myosin Va (Nightingale *et al.*, 2009; Rojo Pulido *et al.*, 2011b; Conte *et al.*, 2016). However, Rab27a has also been shown to serve as a positive regulator of stimulated WPB secretion, in this case exerting its role via another effector, the synaptotagmin-like protein Slp4a (Bierings *et al.*, 2012). Thus Rab27a appears to fulfill several functions in WPB exocytosis, with its activity being controlled by interaction with MyRIP and Slp4a, respectively, and possibly other effectors not yet identified.

Once WPBs are committed to exocytosis, the actual fusion reaction is mediated by one or several different soluble *N*-methylmaleimide–sensitive factor attachment protein receptor (SNARE) complexes. WPB-associated VAMP3 and plasma membrane–localized syntaxin-4 and SNAP-23 form a trans-SNARE complex that mediates Ca²⁺-evoked WPB exocytosis and possibly functions in conjunction with accessory proteins such as StxBP1 and StxBP5 (Munc18-1 and -5; Matsushita *et al.*, 2003; Rojo Pulido *et al.*, 2011a; van Breevoort *et al.*, 2012, 2014). However, it is unknown how the cortically anchored WPBs are transferred to the fusion-mediating SNARE machinery after secretagogue stimulation and whether a plasma membrane–tethered WPB intermediate is formed in the course of acute WPB exocytosis.

To identify endothelial cell components involved in a plasma membrane tethering of WPBs, we focused on Munc13 proteins, which are believed to function as tethering/priming factors in other Ca²⁺-dependent exocytotic events (for a review, see James and Martin, 2013). We show here that two Munc13 isoforms, Munc13-2 and Munc13-4, are expressed in endothelial cells. One of them, the Rab27a effector Munc13-4, localizes to WPBs and stimulates WPB exocytosis—independently, however, of its interaction with Rab27a. Histamine stimulation triggers a clustering of Munc13-4 at sites of WPB–plasma membrane contact that is mediated by the terminal C2 domains of the protein. In search of novel interactors of these C2 domains, we identify the S100A10 subunit of the AnxA2-S100A10 complex. AnxA2-S100A10 is recruited to the endothelial plasma membrane after histamine stimulation and participates in the formation and/or stabilization of Munc13-4 clusters at WPB fusion sites. Our data indicate that Munc13-4 tethers fusion-competent WPBs at the plasma membrane via an interaction with the S100A10 subunit of plasma membrane–bound AnxA2-S100A10 complexes.

RESULTS

Munc13-4 is recruited to WPBs in a Rab27a-independent manner

To probe for the expression of different Munc13 isoforms in primary human endothelial cells (HUVECs), we carried out a comprehensive Western blot screen using a panel of Munc13 antibodies. In these experiments, mouse brain and lung lysates from wild-type and Munc13 knockout mice served respectively as positive and negative controls for antibody specificity. The blots revealed that Munc13-2 and Munc13-4 show significant expression, whereas Munc13-1 and Munc13-3 are expressed at very low levels or not at all (Figure 1, a–d). These findings were corroborated by reverse transcription (RT)–PCR analysis (Figure 1e) and are in line with a previous report on the expression of Munc13-4 in HUVECs (Zografou *et al.*, 2012).

In our next experiments, we concentrated on Munc13-4, which was implicated in other regulated exocytosis events in nonneuronal cells, including the ATP/vascular endothelial growth factor (VEGF)/ basic fibroblast growth factor (bFGF)–triggered release of VWF from endothelial cells (Zografou et al., 2012; James and Martin, 2013). We first established by immunofluorescence staining that endogenous Munc13-4 is present on WPBs (Figure 1f). Different fluorescent protein (FP)–tagged Munc13-4 constructs (green FP [GFP] or yellow FP [YFP]) showed the same WPB localization (Figure 2) and were then used to record the distribution of Munc13-4 in live cells. Because some cytosolic and/or membrane fluorescence was observed in the Munc13-4 staining, the contribution of plasma membrane–associated Munc13-4 to this staining was analyzed directly by using total internal reflection fluorescence (TIRF) microscopy, which records only




FIGURE 2: Munc13-4 localizes to WPBs and the plasma membrane independently of Rab27a. (a) Confocal section of fixed HUVECs expressing YFP–Munc13-4 for 48 h and labeled with anti-VWF and Alexa Fluor 568–conjugated secondary antibodies. (b) TIRF section of live HUVECs expressing YFP–Munc13-4 and the Pl(4,5)P₂-binding domain PLCô4-PH-mKate as membrane marker. (c) Confocal section of fixed HUVECs expressing GFP–Munc13-4(Δ 280-285), a mutant incapable of binding Rab27a, and labeled with anti-VWF and Alexa Fluor 568–conjugated secondary antibodies. (d) Confocal section of fixed HUVECs expressing YFP–Munc13-4 and transfected with siRNA against Rab27a (siRab27a) for 48 h. Cells were labeled with anti-VWF and Alexa Fluor 568–conjugated secondary antibodies. Arrowheads mark examples of colocalizations of Munc13-4 and VWF on WPBs. Scale bars, 10 µm.

signals from fluorophores excited within 100–200 nm of the plasma membrane at the glass interface. This revealed that Munc13-4, in addition to localizing to peripheral WPBs residing in the TIRF field, also showed some general colocalization with the plasma membrane marker PLC-PHD, encoding the phosphatidylinositol 4,5-bisphosphate (PI(4,5)P2)-binding domain of phospholipase C δ (Figure 2b). Because Munc13-4 is a known Rab27a effector and Rab27a is highly enriched on WPBs, we analyzed whether Rab27a recruits Munc13-4 to WPBs. To this end, we recorded the localization of a Munc13-4 mutant lacking the Rab27a-binding motif, which was previously identified to encompass residues 280-285 (Elstak et al., 2011). Of interest, this Munc13-4(Δ280-285) mutant still localized to WPBs, indicating that Rab27a is not required for the WPB association of Munc13-4 (Figure 2c). This was corroborated by knockdown experiments revealing that depletion of Rab27a has no effect on the WPB localization of Munc13-4 (Figure 2d; see Supplemental Figure S1a for Rab27a knockdown). WPBs in Rab27a-depleted cells show a less peripheral and more perinuclear distribution. This was reported before and is caused by loss of peripheral anchorage at the cortical cytoskeleton mediated by the Rab27a/MyRIP/myosin Va complex (Nightingale et al., 2009; Rojo Pulido et al., 2011b). When quantified, Munc13-4 colocalized with at least 75% of all WPBs of a cell, regardless of whether Rab27a was present. Similarly, the Rab27a binding-deficient mutant Munc13-4(A280-285) also colocalized with ~75% of all cellular WPBs (Supplemental Figure S1b).

To identify sequences in Munc13-4 that mediate WPB association, we next employed a series of other mutant Munc13-4 constructs and recorded their distribution in HUVECs (for schematic illustrations of the domain structure of Munc13-4, see Figure 3). These analyses revealed that the terminal C2 domains are dispensable but that sequences in the Munc homology domains (MHDs) 1 and 2 are essential for WPB association of Munc13-4 (Figure 3; see Supplemental Figure S2 for quantification of the colocalization). Thus, whereas Rab27a does not participate in targeting Munc13-4 to WPBs, the MHD1/2 region is of critical importance for mediating the WPB association of Munc13-4, possibly by binding to a still-unknown receptor on WPBs.

Munc13-4 supports histamine-induced WPB exocytosis independently of Rab27a

Munc13-4 is associated with WPBs and is involved in other regulated secretory events for example, Ca²⁺-stimulated exocytosis of dense-core granules in mast cells (Neeft

et al., 2005) and ATP/VEGF/bFGF-triggered release of VWF from endothelial cells (Zografou *et al.*, 2012). Thus we next analyzed whether Munc13-4 is functionally involved in histamine-evoked and Ca²⁺-dependent WPB exocytosis in HUVECs. For this purpose, we depleted endogenous Munc13-4 by small interfering RNA (siRNA; Figure 4a)




FIGURE 3: Munc13-4 localizes to WPBs via its MHD1/MHD2 region. TIRF images of live HUVECs expressing different truncated versions of YFP–Munc13-4 and VWF-RFP as WPB marker for 48 h. Right, domain structures of the respective Munc13-4 mutants lacking the C2A (aa 109–284), C2B (aa 904–1047), or parts of the MUN domain (aa 319–901). The first ~100 aa of Munc13-4 of unknown structure were omitted for simplicity. MHD1 (aa 577–677) and MHD2 (aa 788–894) are two regions within the MUN domain with conserved sequences in all Munc13 proteins. (a) Munc13-4(543-1090), which lacks the C2A and parts of MUN domain but contains the entire region around MHD1/2. (b) Munc13-4(1-899), which lacks the C2B but contains the entire MHD1/2 region. (c) Munc13-4(285-917), which lacks C2A and C2B. (d) Munc13-4(1-780), which is truncated after MHD1 and therefore lacks MHD2-C2B. (e) Munc13-4(781-1090), which lacks the entire N-terminal part including MHD1. Arrowheads mark examples of colocalizations of Munc13-4 and VWF on WPBs. Note that mutants containing the MHD1 and MHD2 regions localize to WPBs, whereas those lacking these sequences do not. Scale bars, 10 µm.

and assessed the effect on histamine-stimulated WPB exocytosis by quantifying the amount of VWF released into the cell culture supernatant. Although knockdown of Munc13-4 had no significant effect on total cellular VWF levels (Supplemental Figure S3) and basal VWF secretion, it significantly reduced the histamine-triggered release of VWF (Figure 4b). To verify the specificity of the knockdown effect, we generated a siRNA-insensitive wildtype YFP-Munc13-4 construct that was expressed in siRNA-transfected cells. This construct fully restored histamine-evoked VWF secretion, confirming that Munc13-4 functions as a positive regulator in Ca²⁺-dependent WPB exocytosis. We then assessed whether an interaction with Rab27a is reguired for the activity of Munc13-4 in WPB exocytosis. Therefore we expressed in the siRNA-treated cells a siRNA-insensitive version of the Munc13-4(Δ 280-285) mutant deficient in binding Rab27a. This mutant also efficiently restored histamine-evoked secretion in Munc13-4-depleted cells (Figure 4b). Thus Munc13-4 is a positive regulator of Ca2+-dependent WPB exocytosis, and this function does not depend on Rab27a binding.

Munc13-4 is recruited to membraneassociated WPBs after secretagogue stimulation

We next analyzed whether the intracellular distribution of Munc13-4 is affected by secretagogue stimulation of HUVECs and recorded the dynamic localization of FPtagged Munc13-4 constructs in histaminestimulated HUVECs by live confocal and TIRF microscopy. A quantitative analysis of the respective fluorescence images revealed that histamine triggers an increase of Munc13-4 at WPBs, including those residing in the cell periphery (Figure 5a). To relate the stimulation-induced enrichment of Munc13-4 at peripheral, possibly plasma membrane-tethered WPBs to the actual sites of WPB docking and fusion, we coexpressed YFP-Munc13-4 with VWF-red FP (RFP), which served as a WPB marker. Sites of WPB exocytosis can thus be easily identified by a collapse of the VWF-RFP-labeled, rodlike WPB structure into a round spot that can be recorded with high spatial and temporal resolution by TIRF microscopy. Analyses of fusing WPBs revealed that the YFP-Munc13-4 fluorescence, after an initial increase at the WPB before fusion, rapidly disappears after fusion, that is, when the elongated VWF-RFP-positive WPB structure collapses into a bright fusion spot (Figure 5, b and c, and Supplemental Video Fig5video01). Externalized VWF-RFP, on the other hand, remains present as a round spot at the fusion site for a considerable length of time, probably be-

cause large VWF multimers are trapped at the extracellular matrix on the coverslip.

Next we used live-cell TIRF microscopy to analyze whether histamine stimulation also affects the distribution of YFP-Munc13-4 at




FIGURE 4: Munc13-4 is required for histamine-induced secretion of VWF. (a) HUVECs were treated with unspecific siRNA as control (siControl) or siRNA targeting Munc13-4 (siMunc13-4), and lysates of the respective cells were subjected to Western blot analysis with anti-Munc13-4 antibodies. Probing with anti-a-tubulin (55 kDa) antibodies served as loading control. Note that endogenous Munc13-4 was successfully depleted. (b) ELISA-based VWF secretion assay. HUVECs were transfected with siControl or Munc13-4 targeting siRNA (siMunc13-4) plus expression vectors encoding YFP (control), YFP-Munc13-4, or GFP-Munc13-4(∆280-285), which were both rendered insensitive to the specific Munc13-4 siRNA (see Materials and Methods). In each case, the amount of VWF secreted into the cell culture supernatant was measured by ELISA. Means of at least five independent experiments that were tested for statistical significance by one-way ANOVA with Tukey's test (ns, not statistically significant, * $p \le 0.05$, ** $p \le 0.01$, **** $p \le 0.0001$). Bars represent mean \pm SEM. Numbers of independent experiments: siControl plus YFP or Munc13-4, eight; siControl plus ∆280-285, seven; siMunc13-4 plus YFP or Munc13-4, six; siMunc13-4 plus \triangle 280-285, five.

the plasma membrane before or at the time of the fusion event. Figure 6a shows that the relatively homogeneous plasma membrane signal of Munc13-4, which is seen in addition to the WPB staining in resting cells (see also Figure 2b), becomes concentrated in more distinct foci after histamine treatment. In many cases, these foci colocalized with VWF-RFP-labeled WPBs, which were detectable in the TIRF field and eventually underwent fusion (Figure 6a and Supplemental Video Fig6video02). To better describe the dynamic nature of the FP-Munc13-4 foci, we analyzed TIRF recordings using an object detection algorithm that identifies bright objects of a size range covering the dimensions of WPBs (MorphoQuant; see Materials and Methods for details; Schuberth et al., 2015). The number of Munc13-4-positive objects, most likely reflecting Munc13-4 foci tethering WPBs at the plasma membrane, increased sharply after histamine stimulation and then decreased again with slower kinetics (Figure 6b). The decrease most likely results from a loss of Munc13-4 from sites of WPB fusion and the diffusion of Munc13-4 in the membrane (see also Figure 5, b and c). Also note that not all YFP-Munc13-4-positive foci colocalized with VWF-RFP-labeled WPBs. A considerable number appeared at sites where no VWF-RFP signal was visible in the TIRF field. These might represent tethering sites of older WPBs not labeled with the transiently expressed VWF-RFP; they might reflect a transient enrichment of Munc13-4 at docking sites of other secretory vesicles; and/or they might have arisen from an intrinsic Ca²⁺-induced clustering of membrane-associated Munc13-4.

Because the foregoing data indicate a role of Munc13-4 in tethering fusion-competent WPBs at the plasma membrane, we next used the object detection algorithm together with the expression of Munc13-4 mutants to analyze which Munc13-4 domains are required for foci formation at the plasma membrane. These experiments revealed that both terminal C2 domains are indispensable for this foci formation. Truncations of the C2 domains, as well as point mutations affecting Ca²⁺ binding (Boswell et al., 2012), largely abolished or markedly slowed down the histamine-triggered formation of Munc13-4 foci (Figure 7). As expected from our previous analyses, Rab27a binding was not required for foci formation because the characteristic transient foci were also observed for the Munc13- $4(\Delta 280-285)$ mutant (Figure 7). Together the experiments with mutant Munc13-4 variants indicate that the central MUN domain of Munc13-4 targets the protein to WPBs, whereas after histamine stimulation, the C2A and C2B domains are required for inducing an enrichment of Munc13-4 at WPB-plasma membrane fusion sites before fusion.

Exocytosis of WPBs can also be induced by cAMP-elevating agents such as forskolin, although some differences appear to exist between the Ca2+- and cAMP-dependent pathways (for a review, see Datta and Ewenstein, 2001; Nightingale and Cutler, 2013). Therefore we analyzed whether the transient Munc13-4 foci can also be elicited by forskolin. Of interest, this was not the case (Supplemental Figure S4).

Munc13-4 interacts with the S100A10 subunit of the AnxA2-S100A10 complex

Given the importance of the C2 domains of Munc13-4 in directing the protein to plasma membrane sites where WPB fusions occur, we performed a yeast two-hybrid (YTH) screen with the two C2 domains of Munc13-4 as baits. The predominant potential interaction partner identified in this screen was \$100A10; 42 of the 71 positive clones obtained in the screen with the C-terminal C2 domain contained the complete coding sequence of S100A10 (see Supplemental Information for details). S100A10 is a member of the EF-hand superfamily of Ca²⁺-binding proteins (Figure 8a). It resides in a tight heterotetrameric complex with AnxA2, a Ca2+-regulated phospholipid and plasma membrane-binding protein, and the complex acts as a positive regulator of acute WPB exocytosis by a yet-unknown mechanism (Knop et al., 2004; Brandherm et al., 2013). To confirm the interaction of Munc13-4 with S100A10 and map their respective binding sites, we performed pull-down experiments with recombinantly expressed and purified Munc13-4 and S100A10 derivatives. This revealed that \$100A10 and Munc13-4 directly interact with one another and that both C2 domains of Munc13-4 bind S100A10 (Figure 8b). We also obtained quantitative binding parameters by surface plasmon resonance ($K_D = 0.45 \,\mu$ M; Supplemental Figure S5). Pull-down experiments with different S100A10 mutants revealed that in S100A10, the binding site for Munc13-4 resides in the very C-terminal six residues (amino acids [aa] 91-96; Figure 8c). This region is dispensable for AnxA2 binding (Kube et al., 1992), indicating




FIGURE 5: Histamine stimulation induces an additional recruitment of Munc13-4 to WPBs. (a) Munc13-4 fluorescence signals increase on WPBs after histamine stimulation. Cells expressing YFP-Munc13-4 or Munc13-4-mKate together with VWF-RFP or VWF-GFP were stimulated with histamine and imaged by live-cell confocal microscopy. Image stills were thresholded in ImageJ to create ROIs for Munc13-4-positive WPBs in a cell and compare mean fluorescence intensities of all ROIs soon before and soon after stimulation. Mean fluorescence intensity before stimulation was set to 1, and the increase after stimulation was measured as the n-fold change in mean fluorescence intensity for every individual ROIs. Mean n-fold changes from all individual ROIs (a total of 323 WPBs from at least three independent experiments) were tested for statistical significance by one-sample t test (**** $p \le 0.0001$). (b) Munc13-4 increases and then disappears at a WPB during exocytosis. HUVECs expressing YFP-Munc13-4 and VWF-RFP were stimulated with 100 μ M histamine, and the fusion of individual WPBs with the plasma membrane was recorded by TIRF microscopy. TIRF sections of a single WPB positive for YFP-Munc13-4 and VWF-RFP. The cell was stimulated at t = 0 s, and fusion of this WPB occurred at t = 10 s. See also Supplemental Video Fig5video01. Scale bar, 1 µm. (c) Corresponding mean fluorescence intensities (YFP, RFP) of the WPB shown in b vs. time. The YFP-Munc13-4 signature shows a fluorescence increase on stimulation (t = 0 to 2.5 s) and subsequently a rapid decrease in fluorescence that coincides with the formation of a characteristic VWF fusion spot (t = 10 to 11.5 s).

that S100A10 can bind simultaneously to AnxA2 and Munc13-4. To test whether tripartite AnxA2/S100A10/Munc13-4 complexes do form in endothelial cells, we carried out coimmunoprecipitation (coIP) experiments. These revealed a significant coIP of all three proteins from HUVEC lysates in the absence of Ca²⁺ (Figure 8d; quantification of coIP results for Munc13-4 and S100A10 in Figure 8e). Thus tripartite complexes of S100A10 binding both AnxA2 and Munc13-4 do form in HUVECs, and Munc13-4 is recruited to these complexes via its C2 domains.

Given the likely tethering function of Munc13-4 in WPB exocytosis, we also assessed whether AnxA2-S100A10 participates in a Munc13-4-mediated tethering of WPBs. A prerequisite for such a function would be a histamine-evoked and thus Ca²⁺-induced recruitment of AnxA2-S100A10 to the plasma membrane because the majority of AnxA2-S100A10 resides in the cytoplasm of nonstimulated HUVECs (Knop et *al.*, 2004). As revealed by live-cell TIRF microscopy, histamine stimulation leads to a marked increase of FPtagged AnxA2 and S100A10 at the plasma membrane, most likely due to a membrane translocation from the cytosol (Supplemental Figure S6, a and b; see also Supplemental Videos FigS6video03 and FigS6video04). Some of the translocated S100A10 also becomes enriched at the stimulation-induced Munc13-4 foci that occur at sites of WPB tethering and fusion (Supplemental Figure S6c; see also Supplemental Video FigS6video05).

Next we analyzed a potential role of AnxA2-S100A10 in the formation and/or stabilization of the Munc13-4 tethers. We depleted HUVECs of AnxA2 and S100A10 by siRNA knockdown and determined the level of Munc13-4 at WPB docking/ fusion sites by recording histamine-induced changes in Munc13-4-mKate fluorescence in live HUVECs using TIRF microscopy. As expected, control siRNA-transfected cells show a histamine-triggered increase of WPBassociated Munc13-4-mKate fluorescence that decreases after fusion (Figure 9a). This transient increase is markedly reduced after AnxA2-S100A10 knockdown (Figure 9, a and b), indicative of a function of AnxA2-S100A10 in recruiting Munc13-4 to WPBplasma membrane contact sites or stabilizing Munc13-4 clusters at these sites.

Finally, we determined whether the interaction of Munc13-4 with AnxA2-S100A10 is functionally relevant for WPB exocytosis. We depleted HUVECs of Munc13-4 or S100A10, or of Munc13-4 plus S100A10, in a double-knockdown approach. We then assessed the effects on histamine-evoked WPB exocytosis by quantifying the amount of secreted VWF. The results confirmed the reduction of histamine-stimulated VWF secretion by Munc13-4 (Figure 4) or S100A10 depletion (Knop et al., 2004). Of importance, the simultaneous knockdown of Munc13-4 and S100A10 had no additional inhibitory effect (Figure 9c; see Supplemental Figure S7 for knockdown efficiency). This suggests that the proteins function in a

common pathway and supports the notion that a tripartite Munc13-4/S100A10/AnxA2 complex is a positive regulator of WPB exocytosis.

DISCUSSION

WPBs are secretory organelles of vascular endothelial cells that serve an important role in controlling blood vessel homeostasis. WPB exocytosis exposes the adhesive platelet and leukocyte receptors VWF and P-selectin, thereby rapidly converting the antiadhesive endothelial surface to an adhesive one, for example, after blood vessel injury or local inflammatory activation. Hence the exocytosis of WPBs has to be strictly regulated and can be evoked by secretagogue stimulation and the subsequent transient increase in intracellular Ca²⁺. Although this Ca²⁺-dependent WBP exocytosis is well documented, the Ca²⁺ sensors and tethering/priming factors involved are not known. Here we identify a novel complex consisting of Munc13-4 and AnxA2-S100A10 as a positive regulator of Ca²⁺-evoked WPB exocytosis. Munc13-4 is present on WPBs in resting endothelial cells and clusters at sites of WPB exocytosis after histamine stimulation. It interacts directly with the S100A10 subunit




FIGURE 6: Histamine stimulation induces a clustering of Munc13-4 at or close to the plasma membrane. (a) TIRF sections of live HUVECs expressing YFP–Munc13-4 and VWF-RFP as WPB marker and stimulated with 100 µM histamine at t = 0 s. Before stimulation, YFP-Munc13-4 shows a general plasma membrane localization and is present on VWF-RFP–positive WPBs that reside in the TIRF field (examples marked by filled arrowheads). Some YFP-Munc13-4–positive objects that are shaped like WPBs but do not contain VWF-RFP can also be weakly seen against the general background (examples marked by open arrowheads). Stimulation triggers an additional clustering of Munc13-4 (t = 3 s), that is, the Munc13-4–positive objects become brighter as more Munc13-4 is recruited to them (see also Figure 5 for WPB-associated Munc13-4). WPB exocytosis, which is accompanied by the formation of a characteristic VWF-RFP fusion spot, leads to a disappearance of the Munc13-4–positive clusters. Arrowheads mark examples of Munc13-4–positive objects that colocalize with VWF-RFP and disappear after WPB fusion (fusion here occurred mainly between t = 3 and 27 s). Scale bar, 10 µm. See also Supplemental Video Fig 6video02. (b) Number of Munc13-4–positive objects in the TIRF field vs. time for the cell shown in a.

of the AnxA2-S100A10 complex, which is recruited to the plasma membrane after secretagogue stimulation and facilitates Munc13-4 clustering, and both Munc13-4 and AnxA2-S100A10 are required for efficient histamine-stimulated WPB exocytosis.

Munc13-4 functions in regulated exocytosis in different nonneuronal cells, often of hematopoietic origin, including mast cells, endothelial cells stimulated with a mixture of ATP/VEGF/bFGF, and cytotoxic T-lymphocytes (Feldmann *et al.*, 2003; Neeft *et al.*, 2005; Zografou *et al.*, 2012). It has been suggested that the protein acts as a tethering and priming factor in granule–plasma membrane interactions, although direct evidence for these tethers is lacking (James and Martin, 2013). Our data are in line with a tethering function of Munc13-4 and provide evidence for the existence of tethering complexes in endothelial cells because we see an increased FP-Munc13-4 signal in distinct plasma membrane foci that are induced by secretagogue stimulation and coincide with WPB fusion sites. In resting HUVECs, Munc13-4 is found on WPBs, although a fraction of the protein also resides at the plasma membrane and in the cytosol. Histamine stimulation triggers a transient increase at and redistribution of Munc13-4 to the foci that most likely represent WPBtethering complexes. This redistribution requires the terminal C2 domains, indicating that Ca2+-binding and/or specific protein or lipid interactions of these C2 domains are relevant for the tethering function. Because the C2A domain can interact with different syntaxins and the C2B domain can bind certain phospholipids (Boswell et al., 2012), these interactions, induced by secretagogue-stimulated Ca²⁺ increase, could trigger or assist the enrichment of Munc13-4 at WPB fusion sites. Such interactions are likely to occur after complex formation of Munc13-4 with AnxA2-S100A10 following a Ca2+-dependent translocation of AnxA2-S100A10 to the plasma membrane. In this scenario, subsequent SNARE interactions of plasma membrane-docked Munc13-4 could help stabilize the tether and also initiate priming of tethered WPBs, leading to SNARE-mediated fusion. A function of Munc13-4 in linking tethered WPBs to the SNARE fusion machinery is in line with the finding that the C2A domain binds syntaxins 2 and 4, both of which are implicated in WPB exocytosis (Matsushita et al., 2003; Rojo Pulido et al., 2011a; Boswell et al., 2012).

We show here that histamine stimulation promotes a translocation of cytoplasmic AnxA2-S100A10 to the plasma membrane, most likely by inducing Ca²⁺-dependent phospholipid binding in the AnxA2 subunits (Supplemental Figure S6). In the resulting membrane-bound conformation of AnxA2-S100A10, the two AnxA2 subunits likely face the membrane through direct interaction with acidic phospholipids, such as

phosphatidic acid, PI(4,5)P₂, and/or phosphatidylserine, whereas the S100A10 subunits point toward the cytosol (Menke et al., 2005). The S100A10 subunit is then available for additional interactions, and thereby the entire complex can serve as a Ca²⁺-regulated plasma membrane–targeting module for S100A10-binding proteins. A number of such proteins have been described, such as the Ca²⁺ channels TRPV5 and TRPV6, the sodium channel Nav1.6, and the serotonin 5-HT1B receptor (Okuse et al., 2002; van de Graaf et al., 2003; Svenningsson et al., 2006). Here we identify Munc13-4 as a new S100A10 interaction partner that can use the AnxA2-S100A10 module as a means to trigger and/or stabilize a plasma membrane–bound state required for efficient tethering of WPBs (Figure 9, a and b). In this scenario, AnxA2-S100A10 regulates Munc13-4–mediated tethering, and this function, in turn, is




FIGURE 7: Deletion of C2A or C2B abolishes the stimulation-induced clustering of Munc13-4 at the plasma membrane. TIRF time-lapse movies of live HUVECs expressing YFP-Munc13-4, Munc13-4-mKate or the indicated mutant constructs and VWF-RFP as WPB marker were recorded, and the obtained images were analyzed by the object detection algorithm MorphoQuant. (a) Representative graphs showing the number of Munc13-4-positive objects detected in the TIRF field of HUVECs stimulated with 100 μ M histamine at t = 15 s. Cells were transfected with YFP- or mKate-tagged full-length Munc13-4, Munc13-4 variants with truncated C2 domains, Munc13-4 variants with mutations in the Ca²⁺-binding sites of the C2 domains, or Munc13-4(∆280-285). Munc13-4(543-1090) lacks the C2A domain, Munc13-4(1-899) lacks the C2B domain, and Munc13-4(285-917) lacks both C2A and C2B (Elstak et al., 2011). Munc13-4(C2A*) carries two point mutations in the Ca²⁺-binding site of the C2A domain, Munc13-4(C2B*) carries two analogous point mutations in the Ca²⁺-binding site of the C2B domain, and Munc13-4(C2A*B*) carries these mutations in both C2 domains (Boswell et al., 2012). (b) Change in the number of Munc13-4-positive objects/100 µm² after histamine stimulation. Cells were transfected and stimulated as in a. Means of n-fold changes over all cells from at least five independent experiments were tested for statistical significance by one-way ANOVA with Tukey's test (ns, statistically not significant, **** $p \le 1$ 0.0001, as compared with the wild-type samples). Numbers of cells analyzed: Munc13-4, 33; Munc13-4(543-1090), 27; Munc13-4(1-899), 42; Munc13-4(285-917), 14; Munc13-4 (mKate), 32; Munc13-4(C2A*), 52; Munc13-4(C2B*), 35; $Munc13-4(C2A*B*), 35; Munc13-4(D280-285), 35. Means \pm SEM: 3.5 \pm 0.3, 1.3 \pm 0.03, 1.2 \pm 0.02, 1.2 \pm 0.02, 2.8 \pm 0.1, 1.2 \pm 0.02, 1.2 \pm 0$ 1.8 ± 0.1 , 1.5 ± 0.1 , 1.2 ± 0.02 , and 2.3 ± 0.2 . (c) Munc13-4(C2A*) is recruited more slowly to WPBs. HUVECs expressing VWF-RFP and YFP-Munc13-4 or YFP-Munc13-4(C2A*) were stimulated as in a. Given is the time from stimulation to the peak of Munc13-4-positive objects in the TIRF field. Means over all cells analyzed were tested for statistical significance by unpaired t test (**** $p \le 0.0001$). Means ± SEM: 6.3 ± 0.1 (Munc13-4), 79 ± 8.6 (Munc13-4(C2A*)).

regulated by Ca²⁺-triggered membrane targeting of the AnxA2-S100A10 complex itself.

In other secretory cell types, Munc13-4 function depends on a Rab27a-mediated association with secretory granules that are often considered lysosome related (James and Martin, 2013). However, and in contrast to secretory events involving other lysosomerelated organelles, a Rab27a–Munc13-4 interaction is required neither for recruiting Munc13-4 to WPBs nor for Munc13-4 to promote WPB exocytosis (Figures 2 and 4). Instead, we identified a sequence toward the C-terminal end of the central MUN domain that is indispensable for WPB interaction. The different domains in Munc13-4 therefore integrate several interactions crucial for efficient WPB exocytosis: 1) A MUN domain–mediated anchoring of Munc13-4 to WPBs; 2) a C2 domain–mediated link to AnxA2-S100A10 at the plasma membrane; and 3) an interaction of Munc13-4 with both syntaxins and certain lipids mediated by its C2A and C2B domains, respectively. Thus the mechanism underlying Munc13-4 function in endothelial cells appears to be unique, as it does not involve an interaction with Rab27a. Of interest, FHL3 patients who carry mutations in Munc13-4 show no overt bleeding phenotype, that is, no severe compromise in VWF secretion. This lack of a severe-bleeding phenotype is possibly due to the unperturbed cAMP-dependent WPB exocytosis (Supplemental Figure S6). Future analysis of FHL3 patients might reveal additional subtle




FIGURE 8: Munc13-4 interacts with the S100A10 subunit of the AnxA2-S100A10 complex. (a) Domain structures of Munc13-4 and S100A10. MUN, Munc13-homology domain. (b) S100A10 binds to both C2 domains of Munc13-4. In vitro binding assay with full-length or truncated mutants of Munc13-4 and wild-type S100A10. Bacterially expressed His₆-Munc13-4 derivatives were immobilized on Ni-NTA and incubated with purified S100A10 (Input). After several washing steps, bound S100A10 was eluted as described in *Materials and Methods* (Elution). Lysates of untransformed *E. coli* served as negative

or acute bleeding phenotypes due to altered Munc13-4 activity in endothelial cells.

MATERIALS AND METHODS

Antibodies, plasmids, siRNA, RT-PCR, and surface plasmon resonance

The experimental details are described in the Supplemental Information.

HUVEC culture and transfection

Primary HUVECs were either isolated from umbilical cord veins as described before (Jaffe et al., 1973) and used as fresh or cryoconserved preparations or purchased as cryoconserved pools (Promocell). Cells were maintained in mixed endothelial growth medium (ECGM1 [Promocell]; mixed 1:1 with M199 [Biochrom] and supplemented with 10% fetal calf serum, 20 μ g/ml gentamicin, 15 μ g/ml amphotericin B, and 100 IE heparin) or endothelial growth medium (ECGM2 [Promocell]; supplemented with 20 μ g/ml gentamicin and 15 μ g/ml amphotericin B) and cultured and transfected as described before (Knop *et al.*, 2004). Nearly confluent cells at passages 2–4 were used in all experiments.

Western blot

For the Western blot detection of Munc13 isoforms in HUVECs, we used as controls postnuclear supernatants from mouse brains or lungs that were prepared by homogenization in lysis buffer (320 mM sucrose, 2 mM EDTA, 20 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid [HEPES]/NaOH to pH 7.4) and centrifugation (1000 \times g for 10 min at 4°C). HUVEC lysates were prepared as total lysates by washing a 60-mm plate once with phosphate-buffered saline (PBS) on ice, scratching the cells into 40 µl of sample buffer (6% [wt/vol] SDS, 150 mM Tris/HCl, pH 6.8, 30% [vol/vol] glycerol, 0.01% [wt/vol] bromophenol blue, 10% [wt/vol] dithiothreitol [DTT]), and boiling at 95°C for 10 min. Samples were subjected to SDS-PAGE in 8% acrylamide gels, transferred to a nitrocellulose membrane at 50 mA overnight in Trisglycine buffer (25 mM Tris, 190 mM glycine, 20% [vol/vol] methanol), and blocked for 1 h in Tris-buffered saline containing 0.1% Tween-20 (TBS-T), 5% milk powder, and 5% goat serum. Membranes were incubated with the respective primary antibodies overnight and subsequently with the horseradish peroxidase- or infrared dye-coupled secondary antibodies for 1 h, with extensive washings (TBS-T with 5%

control. The amount of eluted \$100A10 as percentage of \$100A10 input was quantified from at least three different experiments and is given next to the respective mutant panel on the right. Values are means ± SEM. (c) Two C-terminally truncated mutants of \$100A10, S100A10(1-90) and S100A10(1-84), do not bind Munc13-4. In vitro binding assay as described in b with immobilized full-length His₆-Munc13-4 and the two S100A10 truncation mutants. Note that S100A10(1-90). which can still bind AnxA2 (Kube et al., 1992), fails to interact with Munc13-4. (d) CoIP of Munc13-4 and AnxA2-S100A10. Postnuclear HUVEC supernatants were incubated with Dynabeadscoupled antibodies against either Munc13-4 (IP Munc13-4) or rabbit IgGs as negative control (IP IgG). The starting material (Input) and the precipitated proteins were analyzed by SDS-PAGE (15% gel in top and 10% gel in bottom images) and immunoblotting with antibodies against Munc13-4, S100A10 or AnxA2. (e) Relative amount of precipitated Munc13-4 and S100A10 in the immunoprecipitation experiments using either specific anti-Munc13-4 (IP) or control rabbit IgGs (IgG). Band intensities were calculated as percentage of the input material from five independent experiments (one example is shown in d). Bars represent mean \pm SEM.




FIGURE 9: Munc13-4 and S100A10 function together in histamine-induced secretion of VWF. (a, b) Histamine-induced recruitment of Munc13-4 to WPB fusion sites is decreased on AnxA2-S100A10 depletion. HUVECs were transfected for 48 h with VWF-GFP as WPB marker, Munc13-4-mKate, and unspecific siControl RNAs or siRNAs targeting AnxA2-S100A10. Cells were stimulated with histamine at t = 0 s and imaged by live-cell TIRF microscopy, and individual WPB fusion sites were identified by a collapse of the VWF-GFP signal. Image stills were thresholded in ImageJ to create ROIs for Munc13-4-positive WPBs at WPB fusion sites and compare mean fluorescence intensities of all ROIs soon before and soon after stimulation. Mean fluorescence intensity before stimulation was set to 1, and the increase after stimulation was measured as the n-fold change in mean fluorescence intensity. (a) Examples of Munc13-4-mKate mean fluorescence intensity recordings of individual WPBs from cells treated with siControl or siRNAs targeting AnxA2-S100A10, respectively. (b) Comparison of histamine-induced Munc13-4-mKate fluorescence intensity changes of individual WPBs in siControl- and siAnxA2/siS100A10-treated cells at 2.5 s after stimulation. Mean *n*-fold changes from individual ROIs for Munc13-4-mKatepositive WPBs (a total of at least 57 WPBs/condition from at least three independent experiments) were tested for statistical significance by Mann–Whitney U test (** $p \le 0.01$). (c) ELISA-based VWF secretion assay. HUVECs were transfected for 48 h with unspecific siControl or siRNA targeting Munc13-4 (siMunc13-4) or S100A10 (siS100A10), or siRNAs targeting both proteins in a double knockdown (siMunc13-4/siS100A10). In each case, the amount of VWF secreted into the cell culture supernatant was measured by ELISA. Means of four independent experiments tested for statistical significance by one-way ANOVA with Tukey's test (** $p \le 0.01$, **** $p \leq 0.0001$, as related to the control sample). Differences between samples treated with specific siRNA were statistically not significant (ns). Bars represent mean \pm SEM.

milk powder) after each antibody incubation. Signals were detected by chemiluminescence or using the Odyssey Infrared Imaging System (LI-COR). For Western blot detection of S100A10 and AnxA2, we used standard procedures and 10% or 15% SDS-PAGE gels.

VWF secretion assay

HUVECs were stimulated with 100 μ M histamine (Sigma-Aldrich) or 1 μ M ionomycin, and the amount of secreted VWF was quantified by enzyme-linked immunosorbent assay (ELISA) as previously described (Rojo Pulido *et al.*, 2011b), analyzing three triplicate samples per condition (supernatant of unstimulated cells, of stimulated cells, and total lysates). The amount of VWF secreted into the cell culture supernatant was then expressed as percentage of total VWF content (amount of VWF of all three samples summed, that is, supernatant of nonstimulated plus supernatant of stimulated cells plus remaining total lysate). This analysis allowed us to control for differences in total VWF content between each replicate and each condition.

Yeast two-hybrid screening

Bait vectors encoding the LexA DNA-binding domain in-frame with rat Munc13-4 (GenBank accession number AF159356 [Koch et al., 2000]; residues 1–303 [N-terminal C2] or 888–1088 [C-terminal C2]) were constructed in pLexN (Vojtek et al., 1993; Betz et al., 1997). Yeast two-hybrid (YTH) screens using a rat lung cDNA MATCHMAKER prey library in pACT2 (Clontech) were performed as described (Fields and Song, 1989; Betz et al., 1997).

The YTH screen with the N-terminal C2 domain of Munc13-4 yielded 78 positive clones from 31 million double transformants. Of these, 37 encoded the full-length cardiac troponin 1 (Tnni3), and 18 encoded the GA-BA_A-receptor-associated protein Gabarap. All 18 Gabarap clones encoded the complete C-terminus of the protein but lacked the codons for the first 10 (11 clones) or 43 N-terminal residues (seven clones). Less frequently isolated positive prey clones (each <5% of the total) encoded fragments of Rgs3, Ulc1, Ndn, and Rps18. The YTH screen with the C-terminal C2 domain of Munc13-4 yielded 71 positive clones from 170 million double transformants. Of these, 42 contained the complete coding sequence of S100A10, and 12 encoded the complete coding sequence of sorting nexin 5 (Snx5). Less frequently isolated positive prey clones (each <5% of the total) encoded fragments of Naa10, Scgb1a1, Tdrd7, Eif1a, and Rps18.

Coimmunoprecipitation

For the immunoprecipitation of Munc13-4, we used rabbit polyclonal anti–Munc13-4 (Proteintech, or sc-50465; Santa Cruz Biotechnology) and, as control, nonspecific rabbit immunoglobulin Gs (IgGs) that were coupled to anti-rabbit IgG Dynabeads (Invitrogen) or Protein A-Agarose beads (Santa

Cruz Biotechnology). HUVECs were washed twice with ice-cold PBS, harvested with a cell scraper and collected by low-speed centrifugation. The cell pellets were resuspended in ice-cold lysis buffer (20 mM HEPES, pH 7.4, 150 mM NaCl, 0.5% NP-40, Complete EDTA-free Protease Inhibitor Cocktail [Roche]) and lysed by passage through a 23-gauge needle, and postnuclear supernatants (PNS) were prepared by centrifugation of the lysates (1000 × g, 10 min, 4°C). Immunoprecipitations were carried out by incubating the PNS with the respective beads for 2 or 4 h at 4°C and subsequently washing the beads three times with ice-cold lysis buffer or washing buffer (20 mM HEPES, pH 7.4, 500 mM NaCl, 0.5% NP-40) using a magnetic particle concentrator (Invitrogen) or low-speed centrifugation. After the last wash, proteins bound to the beads were released by resuspending the beads in SDS protein loading buffer (50 mM Tris-HCl, pH 6.8, 2% [wt/vol] SDS, 10% [vol/vol] β -mercaptoethanol,

10% [vol/vol] glycerol, 0.1% [wt/vol] bromophenol blue] and analyzed by Western blotting with rabbit and goat polyclonal anti-Munc13-4 antibodies, anti-S100A10 and anti-AnxA2 antibodies, and infrared dye-coupled secondary antibodies as described earlier (Western blot).

Expression of hexahistidine-tagged Munc13-4 derivatives

Hexahistidine (His₆)-tagged derivatives of Munc13-4 were expressed in *Escherichia coli* (BL21) after overnight induction with 0.1 mM isopropyl- β -D-thiogalactoside (IPTG) at 25°C to reduce protein misfolding and degradation. Bacteria were harvested by centrifugation and resuspended in lysis buffer (40 mM HEPES, pH 7.5, 20 mM imidazole, 300 mM NaCl, 1 mM EDTA, 10 mM 2-mercaptoethanol, Complete EDTA-free Protease Inhibitor Cocktail). Cell lysis was achieved by four freeze/thaw cycles and six 1-min sonication steps, and soluble lysates containing His₆-tagged Munc13-4 were obtained by ultracentrifugation (100,000 × g, 1 h, 4°C).

Expression and purification of untagged S100A10

Bacterial expression of \$100A10 followed a similar protocol as the one used for His₆-tagged derivatives of Munc13-4), but treatment with 1 mM IPTG for 4 h at 37°C was used for induction of recombinant protein expression, and a modified lysis buffer was used (200 mM Tris/HCl, pH 7.5, 200 mM NaCl, 10 mM MgCl₂, 1 mM NaN₃, 2 mM DTT, Complete EDTA-free Protease Inhibitor Cocktail). Different protocols were then used to prepare wild-type S100A10 or the truncated S100A10 mutants (residues 1–90, 1–84). Wild-type S100A10 was purified from the soluble bacterial lysate by ion exchange chromatography in two consecutive steps (modified after Kube et al., 1992), using the weak anion exchanger DEAE-Sephacel (GE Healthcare; diethylaminoethyl [DEAE] buffer, 20 mM imidazole, pH 7.5, 50 mM NaCl, 2 mM DTT, 5 mM EDTA, 0.5 mM EGTA, 1 mM NaN₃) and applying the flowthrough to the weak cation exchanger CM52 cellulose (Whatman; carboxymethyl [CM] buffer, 20 mM sodium acetate, pH 5.6, 2 mM DTT, 0.5 mM EDTA, 0.5 mM ethylene glycol tetraacetic acid, 1 mM NaN₃). After extensive washing with CM buffer and CM buffer containing 100 mM NaCl, wild-type S100A10 was eluted with 500 mM NaCl in CM buffer. S100A10(1-90) and S100A10(1-84) could not be eluted from the CM matrix material and were purified using a different protocol (Ayala-Sanmartin et al., 2000). Briefly, cleared bacterial lysates were first subjected to (NH₄)₂SO₄ precipitation at 50% saturation. After centrifugation (50,000 \times g, 30 min), the nonprecipitated fraction was applied to a phenyl Sepharose matrix (GE Healthcare) that retained the S100A10 derivatives. The matrix was washed with loading buffer, and bound proteins were eluted with decreasing concentrations of $(NH_4)_2SO_4$ in lysis buffer (50, 25, 15, and 0% saturation of $(NH_4)_2SO_4$). The last two fractions containing the S100A10 derivatives were applied to DEAE-Sephacel equilibrated in DEAE buffer. The column was washed with DEAE buffer containing 100 mM NaCl, and proteins were eluted with 300 mM NaCl in DEAE buffer.

In vitro binding assay with ${\rm His}_6{\rm -Munc13-4}$ variants and S100A10

Soluble fractions of His₆–Munc13-4 or cleared lysates of untransformed BL21 bacteria as control were incubated with Ni–nitriloacetic acid (NTA) beads equilibrated in assay buffer (40 mM HEPES, pH 7.5, 20 mM imidazole, 300 mM NaCl, 0.5 mM EDTA, 10 mM 2-mercaptoethanol, 1 mM CaCl₂) for 15 min at 4°C. After two washings with 10 column volumes of assay buffer, equal amounts of wild-type

or mutant S100A10 dialyzed against assay buffer were applied to the column. After several washings with 10 column volumes of assay buffer, His_6 –Munc13-4 and potentially interacting S100A10 were released with elution buffer containing 300 mM imidazole (300 mM imidazole, 300 mM NaCl, 1 mM MgCl₂, 10 mM 2-mercaptoethanol) in several steps. Samples of all steps were run on 15% SDS–PAGE gels, transferred to nitrocellulose membranes, and analyzed by probing with anti-pentahistidine and anti-S100A10 (H21) antibodies as described (see Western blot).

Confocal and TIRF microscopy

Cells were grown on collagen-coated coverslips or chambered slides (Nunc Labtek Chambered Coverglass) for 48 h after transfection if not stated otherwise. For analysis of fixed cells, samples were treated with 4% paraformaldehyde (30 min, room temperature) or methanol (10 min, -20°C), permeabilized with 0.1% Triton X-100 (15 min, room temperature), and mounted in Mowiol. Live cells were imaged in medium supplemented with 25 mM HEPES at 37°C. Confocal imaging used a Zeiss LSM780 confocal microscope and a Plan-Apochromat 63×/1.4 oil immersion objective. Confocal videos were recorded at different speeds. TIRF imaging was performed with an Olympus IX71 TIRF Microscope customized to include a heated incubation chamber, an objective-type TIRF microscopy setup from TILL Photonics, a monochromator for epifluorescence excitation, and a controller allowing hardware-controlled fast switching between total internal reflection fluorescence and epifluorescence (TILL Photonics). Images were acquired using a TILL Image QE charge-coupled device camera (TILL Photonics) and MetaMorph Software (Molecular Devices). The total internal reflection angle was manually adjusted for every experiment. TIRF time-lapse movies were recorded with 2-5 frames/s. Image analysis was performed in ImageJ.

Stimulation-induced recruitment of Munc13-4 to WPBs

Stimulation-induced recruitment of Munc13-4 to WPBs was measured in TIRF microscopy recordings or confocal sections of cells expressing VWF-RFP or VWF-GFP and YFP-Munc13-4 or Munc13-4mKate, respectively. Image stills were thresholded in ImageJ to create regions of interest (ROIs) for Munc13-4-positive WPBs in a cell and to compare mean fluorescence intensities of all ROIs before and after stimulation. ROIs were manually inspected to delete those that did not include the same WPBs in both frames because the WPBs had moved. Mean fluorescence intensities before stimulation were set as 1; the increase after stimulation was measured as the *n*-fold change in mean fluorescence intensities for every individual ROI. Mean n-fold changes from all individual ROIs were tested for statistical significance by one-sample t test from 323 WPBs and seven independent experiments (Figure 5) and by Mann-Whitney U test from at least 57 WPBs/condition and at least three independent experiments (Figure 9, b and c).

Automated object detection

Munc13-4–positive objects were detected in TIRF live recordings before and after stimulation using the Matlab-based image processing algorithm MorphoQuant, which was originally developed to detect Golgi structures (Schuberth *et al.*, 2015). MorphoQuant is freely available (https://github.com/tischi/MorphoQuant). The algorithm detects locally bright large objects of arbitrary shape. The algorithm used a top-hat filter with a circular structural element whose radius, *r1*, was defined to include a typical WPB (*r1* = 15 pixels, with 1 pixel \approx 133 nm). This filter segmented images into a foreground image containing Munc13-4–positive objects and a background image representing the Munc13-4 at the plasma membrane. Subsequent filtering steps improved the distinction between foreground objects and background signal based on their relative fluorescence intensity, defined by an adjustable threshold, t1 (t1 = 8 a.u.). The procedure identified Munc13-4–positive bright objects (adjusted by t1) of a defined size (adjusted by r1) but otherwise arbitrary shape. We visually confirmed that object detection was accurate and that objects showed the typical elongated shape of WPBs. Data were prepared in Excel to illustrate the number of Munc13-4–positive objects and fluorescence of Munc13-4 on objects or nonobjects over time.

Quantification of colocalization of Munc13-4 with WPBs

The fluorescence intensities of VWF were plotted across each WPB using ImageJ. The same cross section was plotted for the Munc13-4 fluorescence channel. WPBs were counted as Munc13-4 positive if the Munc13-4 fluorescence at the WPB fluorescence intensity peak was at least 1.5 times higher than background. At least 300 WPBs from at least three individual experiments were quantified for each condition.

Statistical analysis

Statistical analyses were performed with GraphPad Prism 6 as indicated in the figure legends. Significance threshold was p < 0.05. We tested for normal distribution with the D'Agostino–Pearson omnibus test. When single data sets were not normally distributed, we confirmed the validity of the one-way analysis of variance (ANOVA) or *t* test by nonparametric Kruskal–Wallis or Mann–Whitney test. Mean values are expressed as mean ± SEM. In box plots, boxes extend from the 25th to the 75th percentile, whiskers extend from the 10th to the 90th percentile, a line represents the median, and dots indicate outliers.

ACKNOWLEDGMENTS

We thank Ines Rojo Pulido for initial experiments on the S100A10– Munc13-4 interaction. This work was supported by grants from the German Research Council (GE514/6-2 and GE514/10-1 to V.G.), the National Institutes of Health (DK025861 to T.F.J.M.), and the Dutch Cancer Society (UU2003-2958 to P.v.d.S.).

REFERENCES

- Ayala-Sanmartin J, Gouache P, Henry J-P (2000). N-terminal domain of annexin 2 regulates Ca²⁺-dependent membrane aggregation by the core domain: a site directed mutagenesis study. Biochemistry 39, 15190–15198.
- Betz A, Okamoto M, Benseler F, Brose N (1997). Direct interaction of the rat unc-13 homologue Munc13-1 with the N terminus of syntaxin. J Biol Chem 272, 2520–2526.
- Bierings R, Hellen N, Kiskin N, Knipe L, Fonseca A-V, Patel B, Meli A, Rose M, Hannah MJ, Carter T (2012). The interplay between the Rab27A effectors Slp4-a and MyRIP controls hormone-evoked Weibel-Palade body exocytosis. Blood 120, 2757–2767.
- Boswell KL, James DJ, Esquibel JM, Bruinsma S, Shirakawa R, Horiuchi H, Martin TFJ (2012). Munc13-4 reconstitutes calcium-dependent SNAREmediated membrane fusion. J Cell Biol 197, 301–312.
- Brandherm I, Disse J, Zeuschner D, Gerke V (2013). cAMP-induced secretion of endothelial von Willebrand factor is regulated by a phosphorylation/dephosphorylation switch in annexin A2. Blood 122, 1042–1051.
- Conte IL, Hellen N, Bierings R, Mashanov GI, Manneville J-B, Kiskin NI, Hannah MJ, Molloy JE, Carter T (2016). Interaction between MyRIP and the actin cytoskeleton regulates Weibel–Palade body trafficking and exocytosis. J Cell Sci 129, 592–603.

- Cooper B, Hemmerlein M, Ammermuller J, Imig C, Reim K, Lipstein N, Kalla S, Kawabe H, Brose N, Brandstatter JH, Varoqueaux F (2012). Munc13independent vesicle priming at mouse photoreceptor ribbon synapses. J Neurosci 32, 8040–8052.
- Datta YH, Ewenstein BM (2001). Regulated secretion in endothelial cells: biology and clinical implications. Thromb Haemost 86, 1148–1155.
- Elstak ED, Neeft M, Nehme NT, Voortman J, Cheung M, Goodarzifard M, Gerritsen HC, van Bergen En Henegouwen PM, Callebaut I, de Saint Basile G, et al. (2011). The munc13-4-rab27 complex is specifically required for tethering secretory lysosomes at the plasma membrane. Blood 118, 1570–1578.
- Feldmann J, Callebaut I, Raposo G, Certain S, Bacq D, Dumont C, Lambert N, Ouachee-Chardin M, Chedeville G, Tamary H, et al. (2003). Munc13-4 is essential for cytolytic granules fusion and is mutated in a form of familial hemophagocytic lymphohistiocytosis (FHL3). Cell 115, 461–473.
- Fields S, Song O (1989). A novel genetic system to detect protein-protein interactions. Nature 340, 245–246.
- Jaffe EA, Nachman RL, Becker CG, Minick CR (1973). Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. J Clin Invest 52, 2745–2756.
- James DJ, Martin TFJ (2013). CAPS and Munc13: CATCHRs that SNARE vesicles. Front Endocrinol 4, 187.
- Knop M, Aareskjold E, Bode G, Gerke V (2004). Rab3D and annexin A2 play a role in regulated secretion of vWF, but not tPA, from endothelial cells. EMBO J 23, 2982–2992.
- Koch H, Hofmann K, Brose N (2000). Definition of Munc13-homologydomains and characterization of a novel ubiquitously expressed Munc13 isoform. Biochem J 349, 247–253.
- Kube E, Becker T, Weber K, Gerke V (1992). Protein-protein interaction studied by site-directed mutagenesis. Characterization of the annexin II-binding site on p11, a member of the S100 protein family. J Biol Chem 267, 14175–14182.
- Marks MS, Heijnen HFG, Raposo G (2013). Lysosome-related organelles: unusual compartments become mainstream. Curr Opin Cell Biol 25, 495–505.
- Matsushita K, Morrell CN, Cambien B, Yang S-X, Yamakuchi M, Bao C, Hara MR, Quick RA, Cao W, O'Rourke B, et al. (2003). Nitric oxide regulates exocytosis by S-nitrosylation of N-ethylmaleimide-sensitive factor. Cell 115, 139–150.
- Menke M, Gerke V, Steinem C (2005). Phosphatidylserine membrane domain clustering induced by annexin A2/S100A10 heterotetramer. Biochemistry 44, 15296–15303.
- Neeft M, Wieffer M, de Jong AS, Negroiu G, Metz CH, van Loon A, Griffith J, Krijgsveld J, Wulffraat N, Koch H, et al. (2005). Munc13-4 is an effector of rab27a and controls secretion of lysosomes in hematopoietic cells. Mol Biol Cell 16, 731–741.
- Nightingale T, Cutler D (2013). The secretion of von Willebrand factor from endothelial cells; an increasingly complicated story. J Thromb Haemost 11, 192–201.
- Nightingale TD, Pattni K, Hume AN, Seabra MC, Cutler DF (2009). Rab27a and MyRIP regulate the amount and multimeric state of VWF released from endothelial cells. Blood 113, 5010–5018.
- Okuse K, Malik-Hall M, Baker MD, Poon W-YL, Kong H, Chao MV, Wood JN (2002). Annexin II light chain regulates sensory neuron-specific sodium channel expression. Nature 417, 653–656.
- Rojo Pulido I, Jahn R, Gerke V (2011a). VAMP3 is associated with endothelial Weibel–Palade bodies and participates in their Ca2+-dependent exocytosis. Biochim Biophys Acta 1813, 1038–1044.
- Rojo Pulido I, Nightingale TD, Darchen F, Seabra MC, Cutler DF, Gerke V (2011b). Myosin Va acts in concert with Rab27a and MyRIP to regulate acute Von-Willebrand factor release from endothelial cells. Traffic 12, 1371–1382.
- Sadler JE (1998). Biochemistry and genetics of Von Willebrand factor. Annu Rev Biochem 67, 395–424.
- Schuberth CE, Tängemo C, Coneva C, Tischer C, Pepperkok R (2015). Selforganization of core Golgi material is independent of COPII-mediated endoplasmic reticulum export. J Cell Sci 128, 1279–1293.
- Svenningsson P, Chergui K, Rachleff I, Flajolet M, Zhang X, El Yacoubi M, Vaugeois J-M, Nomikos GG, Greengard P (2006). Alterations in 5-HT1B receptor function by p11 in depression-like states. Science 311, 77–80.
- Valentijn KM, Eikenboom J (2013). Weibel-Palade bodies: a window to von Willebrand disease. J Thromb Haemost 11, 581–592.
- van Breevoort D, Snijders AP, Hellen N, Weckhuysen S, van Hooren KWEM, Eikenboom J, Valentijn K, Fernandez-Borja M, Ceulemans B, Jonghe PD,

et al. (2014). STXBP1 promotes Weibel-Palade body exocytosis through its interaction with the Rab27A effector Slp4-a. Blood 123, 3185–3194.

- Van Breevoort D, van Agtmaal EL, Dragt BS, Gebbinck JK, Dienava-Verdoold J, Kragt A, Bierings R, Horrevoets AJG, Valentijn KM, Eikenboom JC, et al. (2012). Proteomic screen identifies IGFBP7 as a novel component of endothelial cell-specific Weibel-Palade bodies. J Proteome Res 11, 2925–2936.
- Van de Graaf SFJ, Hoenderop JGJ, Gkika D, Lamers D, Prenen J, Rescher U, Gerke V, Staub O, Nilius B, Bindels RJM (2003). Functional expression of the epithelial Ca(2+) channels (TRPV5 and TRPV6) requires association of the S100A10-annexin 2 complex. EMBO J 22, 1478–1487.
- Van Hooren KWEM, van Agtmaal EL, Fernandez-Borja M, van Mourik JA, Voorberg J, Bierings R (2012). The Epac-Rap1 signaling pathway

controls cAMP-mediated exocytosis of Weibel-Palade bodies in endothelial cells. J Biol Chem 287, 24713–24720.

- Varoqueaux F, Sons MS, Plomp JJ, Brose N (2005). Aberrant morphology and residual transmitter release at the Munc13-Deficient mouse neuromuscular synapse. Mol Cell Biol 25, 5973–5984.
- Vojtek AB, Hollenberg SM, Cooper JA (1993). Mammalian Ras interacts directly with the serine/threonine kinase Raf. Cell 74, 205–214.
- Wagner DD, Frenette PS (2008). The vessel wall and its interactions. Blood 111, 5271–5281.
- Zografou S, Basagiannis D, Papafotika A, Shirakawa R, Horiuchi H, Auerbach D, Fukuda M, Christoforidis S (2012). A complete Rab screening reveals novel insights in Weibel-Palade body exocytosis. J Cell Sci 125, 4780–4790.